PDC and neoplasm: pDC dysfunction in the tumor microenvironment, however, remains a barrier to successful therapy and it is reported in some solid tumor models that intra-tumoral administration of CpG fails to reprogram the tolerogenic phenotype of tumor-associated pDC [141].